AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03608774
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.
Trial: NCT00089024
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
Trial: NCT03608774
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.
Trial: NCT00752648
Drug: TMC435350
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02429557
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill given 1 hour before the second heat up tilt
Trial: NCT04669262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match BGB-DXP593
Trial: NCT04669262
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match BGB-DXP604
Trial: NCT01191645
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
Trial: NCT02902302
Drug: Ibuprofen 400 mg/10 mL oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02902302
Drug: MOMENT 400 mg coated tablet
RxNorm normalized name: docosahexaenoic acid / phosphatidylserine Oral Capsule [Senior Moment]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03319953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-041 placebo-matching suspension
Trial: NCT03319953
Drug: Second Generation Antipsychotics (SGA)
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation antipsychotics included risperidone, paliperidone, iloperidone, quetiapine, olanzapine, ziprasidone, asenapine and lurasidone.
Trial: NCT03524963
Drug: Cilostan CR Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostan CR Tab. 200mg once a day for 5 days
Trial: NCT03524963
Drug: Pletaal SR Cap.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pletaal SR Cap. 200mg once a day for 5 days
Trial: NCT00992199
Drug: cisplatin, Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
Trial: NCT00771043
Drug: TYSABRI and AVONEX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TYSABRI and AVONEX treatment per package insert.
Trial: NCT00098748
Drug: Optimized Background Therapy (OBT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBT (3-6 drugs based on treatment history and resistance testing)
Trial: NCT00896337
Drug: Anti-platelet therapy
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
Trial: NCT01795495
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00360464
Drug: Azithromycin SR
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03802344
Drug: MC2-01 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
Trial: NCT03802344
Drug: Cal/BDP combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
Trial: NCT03802344
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream
Trial: NCT01863173
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to control group
Trial: NCT02220855
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03654170
Drug: BI 425809 mixed with [C-14] BI425809
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution
Trial: NCT00585442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00790868
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg
Trial: NCT01689025
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
Trial: NCT06403306
Drug: Ankaferd Blood Stopper (Ankaferd Blood Stopper, Ankaferd Ilaç Kozmetik A.S, Istanbul, Turkey)
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recently introduced to clinical practice as an alternative to FS, is a herbal hemostatic agent. It consists of a standardized mixture of Thymus vulgaris (thyme), Alpinia officinarum (galangal), Vitis vinifera (vine), Glycyrrhiza glabra (licorice) and Urtica dioica (nettle).
Trial: NCT01359254
Drug: Total Body Irradiation (TBI)
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TBI is given twice on the last day.
Trial: NCT03423030
Drug: PBTZ169 Formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBTZ169 Formulation supplied as powder for oral solution
Trial: NCT03423030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo supplied as powder for oral solution
Trial: NCT03423030
Drug: PBTZ169 NCP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBTZ169 NCP supplied as powder for oral solution
Trial: NCT05240157
Drug: Corticosteroid Derivatives
RxNorm normalized name: Corticosteroid derivatives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: observational
Trial: NCT04159610
Drug: WO3970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of cream to each axilla
Trial: NCT04159610
Drug: Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only
Trial: NCT03150966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take placebo in the form of capsules daily during 6 months study period
Trial: NCT02058511
Drug: Anesthesia Premedication, Induction and Maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain.
Trial: NCT02348879
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: contains no active drug
Trial: NCT03907865
Drug: Softacort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
Trial: NCT02797665
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisone 0.6mg/kg/d
Trial: NCT00208936
Drug: Taxol, Cisplatin, 5-Fluorouracil, G-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00464373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4ml NaCl 0.9%
Trial: NCT03821493
Drug: PF-06651600 10 mg tablets
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole.
Trial: NCT01044745
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT00052611
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00308451
Drug: Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)
RxNorm normalized name: biotin / chromium picolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01892436
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01941979
Drug: 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00886886
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules identical to MDMA or Reboxetine
Trial: NCT00643786
Drug: Oxygène
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
Trial: NCT01018134
Drug: Vehicle twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vehicle topical spray administered to affected areas twice daily for 28 days
Trial: NCT00559845
Drug: Epidoxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
Trial: NCT00559845
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m\^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
Trial: NCT03438955
Drug: Omacor + Pritor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
Trial: NCT03438955
Drug: Pritor + Omacor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
Trial: NCT02242435
Drug: 4 mL Injection of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02450383
Drug: Acellular Dermal Matrix
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
Trial: NCT02557100
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00952445
Drug: T0903131 Besylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral
Trial: NCT00952445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily, oral
Trial: NCT00510718
Drug: MDV3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDV3100 daily until progression or dose-limiting toxicity
Trial: NCT02513485
Drug: Levodopa+carbidopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
Trial: NCT02513485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
Trial: NCT02715882
Drug: CBLB502
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02715882
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04668950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will take 2 capsules per day as tolerated for approximately 15 days
Trial: NCT01089439
Drug: Nitric oxide by inhalation INOMAX
RxNorm normalized name: nitric oxide / nitrogen Gas for Inhalation [INOmax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours
Trial: NCT01089439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04675034
Drug: MEDI7352
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC injection of MEDI7352 as stated in arm description.
Trial: NCT03018418
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
Trial: NCT00362583
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00489424
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00489424
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00489424
Drug: Fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01938508
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
Trial: NCT01406938
Drug: AIN457 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1 injection per dose) and placebo to secukinumab 150 mg
Trial: NCT01406938
Drug: AIN457 300mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: secukinumab 150 mg (2 injections per dose)
Trial: NCT03855046
Drug: IncobotulinumtoxinA 50 U Intramuscular Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution.
Trial: NCT02258971
Drug: BEA 2180 BR oral
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT02258971
Drug: BEA 2180 BR infusion
RxNorm normalized name: Respa-BR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion to be reconstituted with isotonic saline
Trial: NCT02926027
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00638976
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES \>33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus \[180 microg/kg\] followed by infusion \[2 microg/kg per minute\] for 18 to 24 hours after the procedure
Trial: NCT04590430
Drug: HFB30132A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to HFB30132A will be administered dose 1 in cohort 1. Participants in Cohort 2 and 3 will receive HFB30132A doses 2 and 3, respectively.
Trial: NCT04779567
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1 gr iv 4 times a day
Trial: NCT04779567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml saline 0.9% iv 4 times a day
Trial: NCT03487588
Drug: A-101 Topical Solution
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-101 Topical Solution applied Day 1, Day 15 and Day 29
Trial: NCT02003638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo provided in the same pill quantity as niacin arm
Trial: NCT00206128
Drug: Seroquel SR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02323126
Drug: EGF816
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF816 150 mg once daily (QD) administered orally as a capsule
Trial: NCT02323126
Drug: INC280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INC280 400 mg twice daily (BID) administered orally as a tablet
Trial: NCT00204594
Drug: rM28
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01058915
Drug: Rosuvastatin 5mg
RxNorm normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5mg/day
Trial: NCT01058915
Drug: Rosuvastatin 40mg
RxNorm normalized name: ROSUVASTATIN 40MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 40mg/day
Trial: NCT00487942
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03520348
Drug: PRO-167
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic
Trial: NCT00712725
Drug: MK3207- 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: MK3207 2.5 mg taken after migraine onset.
Trial: NCT00712725
Drug: MK3207- 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 2: MK3207 5 mg taken after migraine onset.
Trial: NCT00712725
Drug: MK3207- 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 3: MK3207 10 mg taken after migraine onset.
Trial: NCT00712725
Drug: MK3207- 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 4: MK3207 20 mg taken after migraine onset.
Trial: NCT00712725
Drug: MK3207- 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 5: MK3207 50 mg taken after migraine onset.
Trial: NCT00712725
Drug: MK3207- 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 6: MK3207 100 mg taken after migraine onset.
Trial: NCT00712725
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken after migraine onset.
Trial: NCT04801433
Drug: Capotetriol scalp solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capotetriol scalp solution: 30ml/bottle. Two times a day for 4 weeks, topically applied to scalp psoriasis.
Trial: NCT01329276
Drug: Symbicort® forte Turbohaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 µg budesonide / 9 µg formoterol fumarate dihydrate
Trial: NCT00599534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg tablets
Trial: NCT00054327
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04044053
Drug: PF-06865571 400 mg Immediate Release (IR) in Fed State
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg IR dose in fed state
Trial: NCT04044053
Drug: PF-06865571 400 mg MR in Fed State
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg MR in fed state
Trial: NCT04044053
Drug: PF-06865571 400 mg MR in Fasted State
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg MR in fasted state
Trial: NCT01195376
Drug: BEZ235
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02780583
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection administered every 6 hours along with intravenous methylprednisolone
Trial: NCT01700998
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01841125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 15mg, QD(once a day), Oral medication
Trial: NCT00107315
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03359785
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Tablets.
Trial: NCT02141698
Drug: TAK-438 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets
Trial: NCT01713673
Drug: Ulthera System Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused ultrasound energy delivered below the surface of the skin
Trial: NCT01713673
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment using the Ulthera System, but delivering no ultrasound energy.
Trial: NCT01024972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: equiosmolar volume (5% mannitol) every 6 hours x 7 days
Trial: NCT00004112
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, vincristine and doxorubicin as a drip into the bloodstream (intravenously) and prednisolone (steroid) as tablets taken with or after food.
Trial: NCT00004112
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004112
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no